United Therapeutics (UTHR) director sells 50 shares under 10b5-1 plan

Rhea-AI Filing Summary

United Therapeutics director Malcolm Jan reported an open-market sale of company stock. On February 17, 2026, he sold 50 shares of United Therapeutics common stock at a price of $474.68 per share in a transaction coded as an open-market sale.

After this transaction, Jan directly holds 220 shares of United Therapeutics common stock. The sale was carried out under a pre-established Rule 10b5-1 trading plan that he entered into on September 11, 2025, which automates trades according to preset instructions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALCOLM JAN

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		50	D	$474.68	220	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UTHR director Malcolm Jan report?

Malcolm Jan reported selling 50 shares of United Therapeutics common stock. The sale occurred on February 17, 2026, as an open-market transaction at $474.68 per share under a pre-arranged Rule 10b5-1 trading plan.

At what price did Malcolm Jan sell United Therapeutics (UTHR) shares?

He sold the shares at $474.68 per share. The transaction involved 50 shares of United Therapeutics common stock on February 17, 2026, and was reported as an open-market sale under a Rule 10b5-1 trading plan.

How many United Therapeutics shares does Malcolm Jan own after this Form 4?

Following the reported transaction, Malcolm Jan directly owns 220 shares of United Therapeutics common stock. This reflects his holdings after selling 50 shares on February 17, 2026, in an open-market sale at $474.68 per share.

Was the UTHR insider sale by Malcolm Jan under a Rule 10b5-1 plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. The footnote states the plan was entered into on September 11, 2025, and governed the February 17, 2026 open-market sale of 50 United Therapeutics shares.

What role does Malcolm Jan hold at United Therapeutics (UTHR)?

Malcolm Jan is a director of United Therapeutics. The filing identifies his relationship to the issuer as a director, and the reported transaction reflects his personal trading in the company’s common stock, held directly in his own name.

What does transaction code "S" mean in Malcolm Jan’s UTHR Form 4?

Transaction code "S" indicates a sale in the open market or a private transaction. In this case, it refers to Malcolm Jan’s February 17, 2026 sale of 50 United Therapeutics common shares at $474.68 each under a Rule 10b5-1 plan.